罗匹尼罗40-7592，一种儿茶酚-O-甲基转移酶（COMT）抑制剂，联合左旋多巴治疗帕金森病。 - Suppr

Suppr

超能文献

Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease.

作者信息

Limousin P, Pollak P, Gervason-Tournier C L, Hommel M, Perret J E

出版信息

Lancet. 1993 Jun 19;341(8860):1605. doi: 10.1016/0140-6736(93)90750-b.

DOI:10.1016/0140-6736(93)90750-b

PMID:8099689

Abstract

摘要

相似文献

Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease.罗匹尼罗40-7592，一种儿茶酚-O-甲基转移酶（COMT）抑制剂，联合左旋多巴治疗帕金森病。

Lancet. 1993 Jun 19;341(8860):1605. doi: 10.1016/0140-6736(93)90750-b.

Tolcapone: a review of its use in the management of Parkinson's disease.托卡朋：其在帕金森病治疗中的应用综述

CNS Drugs. 2005;19(2):165-84. doi: 10.2165/00023210-200519020-00006.

Tolcapone in the management of Parkinson's disease.托卡朋在帕金森病治疗中的应用

Expert Opin Pharmacother. 2006 Nov;7(16):2263-70. doi: 10.1517/14656566.7.16.2263.

Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.帕金森病患者中左旋多巴联合与不联合托卡朋时的药代动力学-药效学关系。

Clin Pharmacokinet. 2001;40(5):383-93. doi: 10.2165/00003088-200140050-00005.

Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.左旋多巴-苄丝肼和儿茶酚-O-甲基转移酶（COMT）抑制剂托卡朋的急性给药与帕金森病。

Clin Neuropharmacol. 1995 Jun;18(3):258-65. doi: 10.1097/00002826-199506000-00006.

Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.儿茶酚-O-甲基转移酶抑制剂托卡朋对帕金森病患者运动症状及左旋多巴药代动力学的影响。

J Neural Transm (Vienna). 1997;104(2-3):229-36. doi: 10.1007/BF01273183.

Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.儿茶酚-O-甲基转移酶抑制剂托卡朋可延长帕金森病患者左旋多巴/卡比多巴的作用时间。

Neurology. 1993 Dec;43(12):2685-8. doi: 10.1212/wnl.43.12.2685.

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.托卡朋抑制儿茶酚-O-甲基转移酶可减少帕金森病波动期患者的“剂末现象”并降低左旋多巴的用量。

J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):421-8. doi: 10.1136/jnnp.63.4.421.

Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.托卡朋，一种用于治疗帕金森病的选择性儿茶酚-O-甲基转移酶抑制剂。

Pharmacotherapy. 1999 Jan;19(1):6-20. doi: 10.1592/phco.19.1.6.30516.

Influence of COMT inhibition on levodopa pharmacology and therapy.儿茶酚-O-甲基转移酶抑制对左旋多巴药理学及治疗的影响。

Neurology. 1998 May;50(5 Suppl 5):S26-30. doi: 10.1212/wnl.50.5_suppl_5.s26.

引用本文的文献

Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility.新型非硝基儿茶酚儿茶酚-O-甲基转移酶抑制剂调节前额叶皮质多巴胺能神经传递，改善认知灵活性。

Psychopharmacology (Berl). 2020 Sep;237(9):2695-2707. doi: 10.1007/s00213-020-05566-0. Epub 2020 May 30.

Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.儿茶酚-O-甲基转移酶（COMT）抑制剂作为帕金森病辅助治疗的临床潜力。

CNS Drugs. 1994 Mar;1(3):172-9. doi: 10.2165/00023210-199401030-00002.

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.用于治疗帕金森病中左旋多巴诱导并发症的儿茶酚-O-甲基转移酶抑制剂

Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD004554. doi: 10.1002/14651858.CD004554.pub2.

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.儿茶酚-O-甲基转移酶抑制剂在帕金森病中的临床药理学、治疗用途及潜力

Drugs. 2000 Jun;59(6):1233-50. doi: 10.2165/00003495-200059060-00004.

Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.单胺氧化酶A和B以及儿茶酚-O-甲基转移酶抑制对左旋多巴诱导的转圈行为的影响。

J Neural Transm (Vienna). 1997;104(6-7):593-603. doi: 10.1007/BF01291878.

Parkinson's disease.帕金森病

Postgrad Med J. 1997 May;73(859):257-64. doi: 10.1136/pgmj.73.859.257.

Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.儿茶酚-O-甲基转移酶/单胺氧化酶抑制剂与左旋多巴在MPTP处理小鼠中的协同相互作用。

J Neural Transm Gen Sect. 1995;102(1):19-34. doi: 10.1007/BF01276562.

Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.儿茶酚-O-甲基转移酶（COMT）抑制剂托卡朋与单剂量左旋多巴之间的药代动力学-药效学相互作用。

Br J Clin Pharmacol. 1995 Sep;40(3):253-62. doi: 10.1111/j.1365-2125.1995.tb05781.x.

Parkinson's disease.帕金森病

Postgrad Med J. 1995 Apr;71(834):201-3. doi: 10.1136/pgmj.71.834.201.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验